Eli Lilly is taking a significant step to address surging demand for its injectable drugs by acquiring a manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals. The announcement comes amid a broader industry trend of drugmakers scrambling to keep pace with patient needs.

The 84,000-square-foot plant, which recently received FDA approval, will be dedicated solely to the production of Lilly medications. While the company declined to confirm whether its popular diabetes and obesity treatments, Mounjaro and Zepbound (known as Mounjaro for diabetes), will be specifically manufactured there, the acquisition clearly targets this growing market segment.

This article was featured in the iBIO NewsBrief. Get the daily email that keeps you informed and connected in the life sciences industry. Subscribe